increased risk of heart attacks in patients taking Telzir (fosamprenavir) for HIV

September 2009

Health Canada is now warning about an increased risk of heart attacks in patients taking Telzir (fosamprenavir) for HIV.

Telzir is a protease inhibitor that's usually given with low-dose ritonavir and other HIV drugs.

Now some evidence suggests that Telzir increases cardiac risk.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Cardiology warfarin used in combo with aspirin AND clopidogrel (Plavix) in more cardiac patients
Psychiatry Seroquel XR (quetiapine) is the first atypical antipsychotic approved for major depressive disorder
Ophthalmology Two new Rx steroid eyedrops called Lotemax and Alrex
Med Administration whether patients should repeat a dose if they vomit after taking an oral medication
Antiarrhythmics Multaq (MUL-tak, dronedarone), a new antiarrhythmic for persistent atrial fibrillation
Gout LOWER colchicine doses for acute gout
Infectious Diseases increased risk of heart attacks in patients taking Telzir (fosamprenavir) for HIV
Respiratory & Allergy whether EpiPen and Twinject needles are long enough to give epinephrine IM
Probiotics A growing number of products with probiotics
Cardiology how to prevent or treat orthostatic hypotension
Geriatrics What's the best way to treat insomnia in the elderly
Gastroenterology rebound acid-related symptoms after stopping proton pump inhibitors (PPIs)